|
Phase 3 Oral Insulin (ORMD-0801) Trials for the Treatment of Type 2 Diabetes: Over 75% Enrollment Completed
Upcoming Milestones:
6-month topline efficacy results from larger ORA-D-013-1 trial expected in 2022
ORA-D-013-2 trial expected to complete enrollment in 2022
Oravax Medical, Inc.: Oral COVID-19 Vaccine
Upcoming Milestones:
Topline data from Phase 1 expected H1 2022
Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022
Phase 2 NASH Trial: 50% Enrollment Completed
Upcoming Milestones:
Enrollment completion expected H1 2022
Topline data expected in H2 2022
Oral GLP-1
Upcoming Milestone:
Bioavailability (PK and PD) expected in H1 2022
https://www.oramed.com/oramed-issues-annual-message-to-shareholders/
Oramed’s Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians
– 76 Percent of the Physicians Responded They “Definitely Would” or “Probably Would” Prescribe Oramed’s Oral Insulin Candidate for Type 2 Diabetes Patients
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
5 | 987 | Oramed Pharmaceuticals Inc. | OttomanRosendahl | Jürgen1964 | 21.05.23 08:11 | |
2 | 27 | oberbayrischer börsenbrief | lancerevo7 | Teras | 12.08.21 02:38 | |
3 | 3 | Oramed | Packard | Global-Invest | 04.01.14 18:20 | |
1 | lol | petruss | petruss | 15.05.07 18:05 | ||
62 | RT 0,89€. | Carpman | BoMa | 02.08.06 16:14 |